Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $1.27 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -17.24%. A quarter ago, it was expected that this company would post a loss of $1.07 per share when it actually produced a loss of $0.79, delivering a surprise of 26.17%. Over the last four quarters, the compa ...

Exhibit 99.1 Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results - THRIVE VRDN-001 global phase 3 clinical trial in active thyroid eye disease (TED) remains on track for topline readout in September 2024 - - THRIVE-2 VRDN-001 global phase 3 clinical trial in chronic TED topline readout expected year-end 2024; enrollment completed in July and exceeded its target - - REVEAL-1 and REVEAL-2, global phase 3 clinical trials for subcutaneous VRDN-003 in patients with ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-1187261 (State or other jurisdi ...

The sudden soaring of the stock price can be attributed to positive investor mindset regarding the progress of Viridian's clinical-stage pipeline. The company is evaluating its lead candidate, VRDN-001 in active and chronic thyroid eye disease (TED) in two separate late-stage studies, namely THRIVE and THRIVE-2, respectively. While top-line data from the THRIVE study is expected in September, data from the THRIVE-2 study is anticipated before this year's end. If the outcomes from both studies are positive, ...

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Louisa Stone – Manager of Investor Relations Steve Mahoney – President and CEO Tom Ciulla – Chief Medical Officer Conference Call Participants Laura Chico – Wedbush Alex Thompson – Stifel Michael Yee – Jefferies Gavin Clark-Gartner – Evercore Rami Katkhuda – LifeSci Capital Gregory Renza – RBC Julian Harrison – BTIG Trevor Allred – Oppenheimer Operator Welcome to the Viridian Therapeutics F ...

| --- | --- | |-------|-----------------------| | | | | | E N G I N E E R I N G | Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36483 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporatio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-1187261 (State or other ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-1187261 (State or other jurisdi ...

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Louisa Stone - Manager, IR Scott Myers - President and CEO Kristian Humer - Chief Financial and Business Officer Dr. Thomas Ciulla - Chief Development Officer Todd James - SVP, Corporate Affairs and IR Conference Call Participants Derek Archila - Wells Fargo Gavin Clark-Gartner - Evercore ISI Thomas Smith - SVB Securities Laura Chico - Wedbush Securities Kalpit Patel - B. Riley Securities Ja ...